The Lemtrada medical trial data demonstrating the treatment&39.

‘The Lemtrada medical trial data demonstrating the treatment's positive impact on relapse prices and disability progression support its potential as a transformational new treatment for relapsing-remitting multiple sclerosis,’ said Norma Deri, M.D., Hosptial Fernandez, Buenos Aires, Argentina Get more information . ‘The acceptance of Lemtrada is very good news for people coping with energetic MS, who are in need of additional treatment options that may offer better efficacy.’ Lemtrada is backed by a intensive and comprehensive clinical advancement program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.